
Commentary|Videos|December 14, 2024
Dr Grinshpun on Ultra-Sensitive ctDNA Detection in HR+ Early Breast Cancer
Author(s)Albert Grinshpun, MD, MSc
Fact checked by: Ashling Wahner , Chris Ryan
Albert Grinshpun, MD, MSc, discusses the utility of ctDNA as a predictive biomarker of endocrine therapy sensitivity in patients with HR+ breast cancer.
Advertisement
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center, discusses a study evaluating the potential utility of circulating tumor DNA (ctDNA) as a predictive biomarker of endocrine therapy sensitivity in patients with hormone receptor (HR)–positive early breast cancer.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5




































